BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of OncoCyte’s PanC-Dx™ diagnostic products for bladder and breast cancer, have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 in Philadelphia. PanC-Dx™ is a class of non-invasive cancer diagnostics based on OncoCyte’s proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte.
Help employers find you! Check out all the jobs and post your resume.
